From: A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma
Grade 1–2
Grade 3–4
N
%
Anemia
19
20
1
Neutropenia
2
0
Thrombocytopenia
12
13
Nausea
3
Vomiting
Anorexia
6
7
Stomatitis
22
Diarrhea
15
16
Fatigue
9
10
Skin
11
Hepatic
Hypertension
24